Abstract
Basal cell and squamous cell carcinomas comprise the majority of non-melanoma skin cancers. Whereas the incidence of skin cancer is equivalent to that of all other cancers combined, non-melanoma skin cancer receives a disproportionate share of attention because mortality is relatively low. However, the impact on public health is striking. This review is intended to update readers on the current findings in research on the prevention of these diseases. Topics covered include preventive strategies targeting high-risk populations, chemoprevention (including treatment of intraepithelial neoplasia), and an overview of recent and ongoing clinical and preclinical studies involving new chemopreventive agents.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Greenlee RT, Hill-Harmon MB, Murray T, et al.: Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15–36. The latest cancer statistics published by the American Cancer Society indicate that acceleration of NMSC incidence may be slowing.
Parker SL, Tong T, Bolden S, et al.: Cancer statistics, 1997. CA Cancer J Clin 1997, 47:5–27.
Greenlee RT, Murray T, Bolden S, et al.: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7–33.
Lee JAH: Epidemiology of cancers of the skin. In Cancer of the Skin. Edited by Friedman RJ, Rigel DS, Kopf AW, et al. Philadelphia: WB Saunders; 1991:14–24.
Lang PG Jr, Maize JC: Basal cell carcinoma. In In Cancer of the Skin. Edited by Friedman RJ, Rigel DS, Kopf AW, et al. Philadelphia: WB Saunders; 1991:35–73.
Demetrius RW, Randle HW: High-risk nonmelanoma skin cancers. Dermatol Surg 1998, 24:1272–1294.
Salasche SJ: Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000, 42:S4-S7.
Jacob A: Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face. Dublin Hospital Reports and Communications in Medicine and Surgery 1827, 4:232–239.
Boukamp P, Popp S, Bleuel K, et al.: Tumorigenic conversion of immortal human skin keratinocytes (HaCaT) by elevated temperature. Oncogene 1999, 18:5638–5645.
Christophers AJ: Melanoma is not caused by sunlight. Mutat Res 1998, 422:113–117.
Harwood CA, McGregor JM, Proby CM, et al.: Human papillomavirus and the development of non-melanoma skin cancer. J Clin Pathol 1999, 52:249–253.
Karagas MR, McDonald JA, Greenberg ER, et al.: Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. The Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996, 88:1848–1853.
Lindelof B, Sigurgeirsson B, Gabel H, et al.: Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000, 143:513–519.
DiGiovanna JJ: Posttransplantation skin cancer: scope of the problem, management, and role for systemic retinoid chemoprevention. Transplant Proc 1998, 30:2771–2778.
Hojo M, Morimoto T, Maluccio M, et al.: Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530–534. This report offers evidence that the tremendous increase in NMSC risk experienced by solid-organ transplant recipients may be due to immunosuppressants like cyclosporine, which can directly promote cancer progression independent of its primary effect on the host’s immune cells.
de Gruijl FR: Skin cancer and solar UV radiation. Eur J Cancer 1999, 35:2003–2009.
Stratton SP, Dorr RT, Alberts DS: The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer 2000, 36:1292–1297.
Smith ES, Feldman SR, Fleischer AB Jr, et al.: Characteristics of office-based visits for skin cancer: dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions. Dermatol Surg 1998, 24:981–985.
Johnson MT, Roberts J: Skin conditions and related need for medical care among persons 1–74 years. United States, 1971–1974. Vital Health Stat 1978, 11:1–72.
Zagula-Mally ZW, Rosenberg EW, Kashgarian M: Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer 1974, 34:345–349.
Frost CA, Green AC: Epidemiology of solar keratoses. Br J Dermatol 1994, 131:455–464.
Boone CW, Kelloff GJ, Steele VE: Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 1992, 52:1651–1659.
Evans C, Cockerell CJ: Actinic keratosis: time to call a spade a spade. South Med J 2000, 93:734–736.
Cockerell CJ: Histopathology of incipient intraepidermal squamous cell carcinoma (’actinic keratosis’). J Am Acad Dermatol 2000, 42:S11-S17. An argument for the elimination of the term "actinic keratosis" in favor of a term that accurately reflects the pathobiology of this lesion.
Lober BA, Lober CW: Actinic keratosis is squamous cell carcinoma. South Med J 2000, 93:650–655.
Brand D, Ackerman AB: Squamous cell carcinoma, not basal cell carcinoma, is the most common cancer in humans. J Am Acad Dermatol 2000, 42:523–526.
Marks R, Foley P, Goodman G, et al.: Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986, 115:649–655.
Marks R, Rennie G, Selwood T: The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch Dermatol 1988, 124:1039–1042.
Moon TE, Levine N, Cartmel B, et al.: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997, 6:949–956. Results of the first successful phase III randomized, double-blinded, placebo-controlled chemoprevention trial, which showed that oral vitamin A successfully prevents SCC in patients with multiple AK.
Thompson SC, Jolley D, Marks R: Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993, 329:1147–1151.
Marks R: Two decades of the public health approach to skin cancer control in Australia: why, how and where are we now? Australas J Dermatol 1999, 40:1–5.
Whited JD, Mills BJ, Hall RP, et al.: A pilot trial of digital imaging in skin cancer. J Telemed Telecare 1998, 4:108–112.
Greenberg ER, Baron JA, Stukel TA, et al.: A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990, 323:789–795.
Clark LC, Combs GF Jr, Turnbull BW, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276:1957–1963.
Green A, Williams G, Neale R, et al.: Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999, 354:723–729.
Frieling UM, Schaumberg DA, Kupper TS, et al.: A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the Physicians’ Health Study. Arch Dermatol 2000, 136:179–184.
Grimaitre M, Etienne A, Fathi M, et al.: Topical colchicine therapy for actinic keratoses. Dermatology 2000, 200:346–348.
Alberts DS, Dorr RT, Einspahr JG, et al.: Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000, 9:1281–1286.
Dorr RT, Dvorakova K, Brooks C, et al.: Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol 2000, 72:526–532. Positive clinical results in a trial using a novel chemopreventive Strategy—induction of a "synthetic suntan" by an analogue of a-melanocyte-stimulating hormone.
Bavinck JN, Tieben LM, van der Woude FJ, et al.: Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995, 13:1933–1938.
Meyskens FL: Cancer population genetics and tumour prevention: an unfulfilled paradigm. Eur J Cancer 2000, 36:1189–1192. See annotation for [42••] below.
Meyskens FL: Cancer prevention in the year 2025: an anticipation. Eur J Cancer 2000, 36:1737–1740. These two articles offer projections of how individual genetic profiling (rapidly becoming a reality) will affect chemoprevention trial design and individually tailored prevention strategies in the future.
McVean M, Xiao H, Isobe K, et al.: Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. Carcinogenesis 2000, 21:633–639.
Fischer SM, Lo HH, Gordon GB, et al.: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999, 25:231–240.
Chow H-HS, Cai Y, Alberts DS, et al.: Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001, 10:53–58.
Gensler HL, Timmermann BN, Valcic S, et al.: Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Nutr Cancer 1996, 26:325–335.
Chen W, Dong Z, Valcic S, et al.: Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line. Mol Carcinog 1999, 24:79–84.
Barthelman M, Chen W, Gensler HL, et al.: Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998, 58:711–716.
Zi X, Agarwal R: Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999, 263:528-.
Huang C, Ma WY, Hanenberger D, et al.: Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997, 272:26325–26331.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stratton, S.P. Prevention of non-melanoma skin cancer. Curr Oncol Rep 3, 295–300 (2001). https://doi.org/10.1007/s11912-001-0080-x
Issue Date:
DOI: https://doi.org/10.1007/s11912-001-0080-x